← 홈

Antibody

1,230개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-6 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,230개
AntibodystaleJules Bordet InstitutePhase 1

trastuzumab (Herceptin, Zr89-trastuzumab)

Breast Neoplasms; Secondary · HER2

#HER2#Antibody#Phase1#항체#면역항체+4
효능 ORR 10%임상시험 1상태 ACTIVE
AntibodystaleM.D. Anderson Cancer CenterPhase 2

^111 In Ibritumomab Tiuxetan (^111 In Ibritumomab Tiuxetan)

Lymphoma · Lymphoma

#Lymphoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 0.8%임상시험 1상태 DISCONTINUED
AntibodystaleUniversity Hospital, Strasbourg…Approved

abatacept, rituximab or tocilizumab (abatacept, rituximab or tocilizumab)

Rheumatoid Arthritis · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Approved#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleJanssenPhase 2

anti TNFa monoclonal antibody - Infliximab (anti TNFa monoclonal antibody - Infliximab)

Endometriosis · Endometriosis

#Endometriosis#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleImperial College LondonPreclinical

etanercept or adalimumab (anti-TNF therapy, anti-TNF therapy (etanercept or adalimumab))

Rheumatoid Arthritis; Ankylosing Spondylitis · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Preclinical#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleJiangsu Cancer Institute & Hosp…Phase 2

QL1706 (apalolimab and toripalimab, apalolimab and toripalimab (QL1706))

NSCLC; NSCLC (Non-small Cell Lung Cancer) · NSCLC

#NSCLC#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleTongji HospitalPreclinical

apatinib plus camrelizumab (apatinib plus camrelizumab)

Hepatocellular Carcinoma Non-resectable · Hepatocellular Carcinoma Non-resectable

#HepatocellularCarcinomaNon-resec#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleNational Cancer Institute (NCI)Phase 2

apolizumab (apolizumab)

Noncontiguous Stage II Small Lymphocytic Lymphoma; Recurrent Small Lymphocytic Lymphoma · FRα

#FR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleIsofol Medical ABPhase 2

ARFOX + bevacizumab (arfolitixorin, arfolitixorin (ARFOX + bevacizumab))

Metastatic Colorectal Cancer (mCRC) · Metastatic Colorectal Cancer (mCRC)

#MetastaticColorectalCancermCRC#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

atezolizumab (Tecentriq, atezolizumab / tiragolumab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleAbbViePhase 3

adalimumab (Humira, azathioprine or adalimumab and infliximab)

Crohn Disease · Crohn Disease

#CrohnDisease#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleMedical University of GrazApproved

etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept (bDMARD withdrawal, bDMARD withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept))

Rheumatoid Arthritis · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Approved#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleSeoul National University Hospi…Phase 2

bendamustine plus rituximab (bendamustine plus rituximab)

Marginal Zone B-cell Lymphoma · Marginal Zone B-cell Lymphoma

#MarginalZoneB-cellLymphoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 81.8%임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

bevacizumab, Rituximab (bevacizumab, Rituximab)

Non-Hodgkin's Lymphoma; B-cell Lymphoma · Non-Hodgkin's Lymphoma

#Non-HodgkinsLymphoma#Antibody#Phase2#항체#면역항체+3
효능 ORR 93.8%임상시험 1상태 DISCONTINUED
AntibodystaleUniversity Hospital, CaenPhase 2

bevacuzimab spray (bevacuzimab spray)

Telangiectasia, Hereditary Hemorrhagic · Telangiectasia, Hereditary Hemorrhagic

#TelangiectasiaHereditaryHemorrha#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleAmgenPhase 1

blinatumomab and auto-HSCT "sandwich " strategy (blinatumomab and auto-HSCT "sandwich " strategy)

B-cell Acute Lymphoblastic Leukemia · B-cell Acute Lymphoblastic Leukemia

#B-cellAcuteLymphoblasticLeukemia#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleSingapore General HospitalPhase 1

bortezomib, rituximab, ifosphamide, etoposide, carboplatin (bortezomib, rituximab, ifosphamide, etoposide, carboplatin)

Diffuse Large B-Cell Lymphoma · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

cTACE+Atirizumab+Bevacizumab (cTACE+Atirizumab+Bevacizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleCentre Francois BaclesseApproved

nivolumab (Opdivo, cabozantinib and nivolumab)

Renal Cell Carcinoma (Kidney Cancer); Metastatic Renal Cell Carcinoma · Renal Cell Carcinoma (Kidney Cancer)

#RenalCellCarcinomaKidneyCancer#Antibody#Approved#항체#면역항체+3
효능 ORR 25%임상시험 1상태 RECRUITING
AntibodystaleSichuan Cancer Hospital and Res…Phase 2

cadonilimab+paclitaxel/albumin-bound paclitaxel+carboplatin (cadonilimab+paclitaxel/albumin-bound paclitaxel+carboplatin)

NSCLC · NSCLC

#NSCLC#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING

56 / 62 페이지

← 이전다음 →